GSK spinout KaNDy raises $32M to fund a breakthrough shot at a women's health drug
Image: Mary Kerr KANDY THERAPEUTICS
For women experiencing symptoms of menopause — hot flashes, sleep and mood problems among others — hormone replacement therapy is often the only relief. But it comes with a cost: From breast swelling to cardiovascular risks, the side effects of such treatment are well known.
KaNDy Therapeutics, a UK biotech created to address this very problem, has just raised $32 million (£25 million) to test out a non-hormonal approach.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.